Around one in five heart patients in cardiac rehabilitation are depressed, anxious or stressed, according to a new study published in the European Journal of Preventive Cardiology.

Evidence published in BMJ Heart last month supports the idea of an “obesity paradox” in heart failure, further complicating a long-running debate as to whether extra weight can be cardioprotective in patients with established CVD.

A 90-minute communication skills course improved conversations about ICD deactivation and goals of care between clinicians and their patients, according to the recently published results of the WISDOM study.

New research suggests the incidence of cardiac amyloidosis in the U.S. is trending up, bringing with it high rates of morbidity and mortality.

Just weeks after it fast-tracked dapagliflozin for the treatment of chronic kidney disease, the FDA announced it was granting Fast Track status to the drug for another indication: heart failure.

Research presented at the ESC Congress in Paris Sept. 2 suggests malaria could be linked to as much as a 30% increased risk of heart failure.

Research out of the Netherlands suggests current clinical guidelines might recommend overtreatment for women with heart failure, who see maximum benefit from HF drugs at half the dose of men.

SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events.